HARROW HEALTH HROW 深 沪
已收盘 08-08 16:00:00 美东时间
34.43
+1.220
+3.67%
华盛通- 最 高35.33
- 今 开33.54
- 成交量 53.34万股
- 最 低 32.91
- 昨 收 33.21
- 总市值 12.64亿
- 52周最高 59.23
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 20.85
- 委 比 -21.65%
- 总股本 3669.96万
- 历史最高 59.23
- 量 比 1.47
- 振 幅 7.29%
- 历史最低 3.33
- 每 手 1
- 风险率 13.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多A Preview Of Harrow's Earnings
Harrow (NASDAQ:HROW) will release its quarterly earnings report on Monday, 2025...
08-08 23:05
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference
Harrow, a leading North American eyecare pharmaceutical company, announced that its CEO, Mark L. Baum, and CFO, Andrew Boll, will participate in H.C. Wainwright’s 5th Annual Ophthalmology Conference on August 13, 2025. Mark will join a fireside chat at 8:30 a.m. ET and participate in a panel discussion on “Novel Treatments for Front-of-the-Eye Indications” at 1 p.m. ET. Both sessions will be webcast live and available on Harrow’s website for 90 d...
08-06 11:00
Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025
Harrow Inc. will announce its Q2 2025 financial results on August 11, 2025, after market close. A conference call and live webcast to discuss the results will be held on August 12, 2025, at 8:00 a.m. Eastern Time. The webcast and call registration details are available on the company’s website. Harrow, a leading North American eyecare pharmaceutical company, focuses on developing innovative ophthalmic products. For more information, visit harrow....
07-29 11:00
Cantor Fitzgerald Initiates Coverage On Harrow with Overweight Rating, Announces Price Target of $76
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Harrow (NASDAQ:HROW) with a Overweight rating and announces Price Target of $76.
07-11 19:59
William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy
Harrow licensed U.S. rights to FDA-approved BYQLOVI for post-surgical eye pain and adds momentum to its branded ophthalmic drug strategy.
06-12 00:58
Assessing Harrow: Insights From 4 Financial Analysts
Harrow (NASDAQ:HROW) has been analyzed by 4 analysts in the last three months, ...
06-10 21:00
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today anno...
06-09 19:00
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock
Jim Cramer takes a look at Harrow, Pfizer, Kinsale Capital, Manulife Financial, Iron Mountain and more on "Mad Money."
05-13 21:09
美股大行评级 | 潜在涨幅455.56%！Medicus Pharma获D. Boral Capital升目标价至27美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1128971739548127232.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• D. Boral Capital：维持Medicus Pharma(MDCX)"买入"评级，目标价从14美元升至27美元</p> <p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从
05-13 08:50
HC Wainwright & Co. Maintains Buy on Harrow, Raises Price Target to $60
HC Wainwright & Co. analyst Yi Chen maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $57 to $60.
05-12 19:08
